A Mitra, A Barua, L Huang, S Ganguly, Q Feng… - Frontiers in …, 2023 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Chimeric antigen receptor (CAR) T cell therapy effectively treats human cancer, but the loss of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine …
OK Dagher, AD Posey Jr - Nature Immunology, 2023 - nature.com
The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented long-term clearance of relapse/refractory hematological malignancies in both pediatric and …
MA Ceja, M Khericha, CM Harris… - The Journal of …, 2024 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments …
SM Reincke, N von Wardenburg, MA Homeyer… - Cell, 2023 - cell.com
Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic …
CA Tsuchida, KM Wasko… - Proceedings of the …, 2024 - National Acad Sciences
Cell-type-specific in vivo delivery of genome editing molecules is the next breakthrough that will drive biological discovery and transform the field of cell and gene therapy. Here, we …
CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To …
S Jilani, JD Saco, E Mugarza, A Pujol-Morcillo… - Nature …, 2024 - nature.com
A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying surface proteins highly expressed in tumors but not in normal tissues …